Sanofi (SAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi's R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has an operational presence in Europe, the Americas, Africa, Asia-Pacific, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.Sanofi Key Recent Developments
- Oct 29, 2024: SandboxAQ Selected by Sanofi for Quantitative AI-Driven Biomarker Identification
- Oct 25, 2024: Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments
- Oct 25, 2024: Sanofi Q3: 15.7% Sales Growth Boosted by Earlier-Than-Anticipated Vaccine Sales; 2024 Business EPS Guidance Raised Due to Strong Business Performance
- Oct 21, 2024: Sanofi’s $17bn sale of Opella to US investors advances following government deal
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck & Co Inc
- Johnson & Johnson
- Boehringer Ingelheim International GmbH
- Bayer AG
- Correvio Pharma Corp
- Pfizer Inc
- Novo Nordisk AS
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Co
- Bristol-Myers Squibb Co
- Qiagen Marseille SA
- Indivior Plc
- GSK plc
- Amgen Inc
- Novartis AG
- Lumos Pharma Inc
- Heska Corp
- AstraZeneca Plc
- Innocoll Holdings Ltd
- Groupe SOLACTIS SAS